Synteka Bio신테카바이오
226330 · KOSDAQ · ₩226330 · 신테카바이오
₩1,059▼ ₩15 (1.40%)End-of-day · Oct 29, 2026 · End-of-day prices.
Margins
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Gross margin | — | — | — | — | — | — |
| Operating margin | −341.3% | −313.9% | −11,804.0% | −9,947.9% | −4,833.0% | −2,807.9% |
| Net margin | −389.1% | −506.8% | −5,966.9% | −9,235.9% | −1,847.0% | −4,674.7% |
Growth (year on year)
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue growth | −10.0% | +2,736.7% | −2.0% | −49.4% | −22.9% | — |
| Operating income growth | +2.1% | +24.6% | −16.2% | −4.1% | −32.6% | — |
| Net income growth | +30.9% | −140.9% | +36.7% | −152.9% | +69.6% | — |
Returns
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Return on equity | −41.6% | −61.3% | −25.7% | −36.4% | −15.3% | −53.6% |
| Return on assets | −28.4% | −38.5% | −14.9% | −21.0% | −7.3% | −21.8% |
Leverage and liquidity
| TTM | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Liabilities to equity | 46.5% | 46.4% | 75.3% | 69.5% | 77.0% | 145.7% |
| Net debt to equity | −4.2% | −29.1% | −19.2% | −57.2% | −79.1% | −20.1% |
| Current ratio | 97.2% | 142.4% | 77.1% | 113.3% | 168.5% | 3,081.7% |
Calculated from filed financial statements. TTM = trailing 12 months.
Also known as: Synteka Bio / 신테카바이오 / 226330 / KRX:226330
Source: KRX statistical information